NEW YORK (GenomeWeb) – Abbott reported today that third quarter sales in its Diagnostics business grew 5 percent year over year, driven by nearly 6 percent increases in both its point-of-care and core-lab diagnostics sales, but offset by a 1 percent decline in molecular diagnostics sales.

For the three months ended Sept. 30, Abbott reported overall Q3 revenues of $5.30 billion, up 3 percent from $5.15 billion in Q3 last year. The company beat the consensus Wall Street estimate of $5.29 billion.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.